Watchlist Price Alert

Xenon Pharmaceuticals Inc... (XENE)

NASDAQ: XENE · Real-Time Price · USD

29.53

-0.21 (-0.71%)

At close: May 15, 2025, 3:59 PM

29.57

0.14%

After-hours: May 15, 2025, 04:43 PM EDT

-0.71% (1D)

Bid	28.5
Market Cap	2.27B
Revenue (ttm)	7.5M
Net Income (ttm)	-251.45M
EPS (ttm)	-3.01
PE Ratio (ttm)	-9.81
Forward PE	-6.55
Analyst	Buy

Ask	30.1
Volume	951,395
Avg. Volume (20D)	854,052
Open	29.77
Previous Close	29.74
Day's Range	29.21 - 30.07
52-Week Range	26.74 - 46.00
Beta	1.22

About XENE

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol XENE

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for XENE stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Xenon Pharmaceuticals has released their quartely earnings on May 12, 2025:

Revenue of $7.5M exceeds estimates by $5.59M, with Infinity% YoY growth.

EPS of -0.83 exceeds estimates by 0.07, with -33.87% YoY decline.

Why Price Moved

2 days ago

-17.43%

Xenon Pharmaceuticals shares are trading lower. Th... Unlock content with Pro Subscription

1 day ago

+2.37%

Xenon Pharmaceuticals shares are trading lower. The company reported Q1 financial results.

News

10 hours ago · proactiveinvestors.co.uk

Polarean's Xenon MRI technology to feature in over 30 studies at American Thoracic Society events

Polarean Imaging PLC (AIM:POLX, OTC:PLLWF), the AIM-listed medical imaging company, will have its Xenon-based magnetic resonance imaging (MRI) technology showcased in more than 30 clinical studies at ...

2 days ago · zacks.com

Xenon Q1 Loss Narrower Than Expected, Pipeline Development in Focus

XENE incurs narrower-than-estimated first-quarter 2025 loss. Studies on lead candidate, azetukalner, in epilepsy and MDD are progressing well.

1 day ago · seekingalpha.com

Xenon Pharmaceuticals Inc. (XENE) Q1 2025 Earnings Call Transcript

Xenon Pharmaceuticals Inc. (NASDAQ:XENE ) Q1 2025 Earnings Conference Call May 12, 2025 4:30 AM ET Corporate Participants Chad Fugere - Vice President, Investor Relations Ian Mortimer - President and ...

1 week ago · zacks.com

Wall Street Analysts See a 48.15% Upside in Xenon Pharmaceuticals (XENE): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 48.2% in Xenon Pharmaceuticals (XENE). While the effectiveness of this highly sought-after metric is questionab...

3 weeks ago · seekingalpha.com

Xenon- A Later Stage Story

Xenon's lead asset, azetukalner, shows promise in treating focal onset seizures with positive phase IIb results and upcoming phase III data expected by end of 2025. Azetukalner's unique Kv7 potassium ...

1 month ago · seekingalpha.com

Xenon Pharmaceuticals Looks Attractive Before Epilepsy Data

Xenon Pharmaceuticals Inc.'s lead asset, azetukalner (XEN1101), shows promising phase 2b results for focal onset seizures (FOS) and is in phase 3 trials for FOS and PGTCS. Despite failing to meet the ...

2 months ago · zacks.com

Xenon Q4 Loss Narrower Than Expected, Pipeline Development in Focus

XENE reports a narrower-than-expected fourth-quarter 2024 loss. Its development programs for azetukalner in epilepsy and MDD are progressing well.

2 months ago · seekingalpha.com

Xenon Pharmaceuticals Inc. (XENE) Q4 2024 Earnings Call Transcript

Xenon Pharmaceuticals Inc. (NASDAQ:XENE ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Chad Fugere - Vice President, Investor Relations Ian Mortimer - President a...